Company intelligence / Profile preview

UtoPharm

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

UtoPharm is a South Korean biotechnology company dedicated to the discovery and development of innovative targeted therapies for cancer and autoimmune diseases. The company leverages its proprietary medicinal chemistry and linker technology to create high-selectivity small molecule inhibitors and next-generation antibody-drug conjugates (ADCs). Its lead candidate, UTO-202, is a selective HDAC6 inhibitor designed to treat multiple myeloma with enhanced efficacy and a superior safety profile compared to pan-HDAC inhibitors. By focusing on precision oncology and immunology, UtoPharm aims to address significant unmet medical needs through improved drug delivery and target specificity.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeAntibody-drug conjugate
Industry: Biotech

Partnerships

Dong-A ST

Beyond the preview

Go deeper on UtoPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UtoPharm.

Explore the full profile